Skip to main content
Account

Table 1 Characterization of all liposomes

From: Preparation and Evaluation of Liposomes Co-Loaded with Doxorubicin, Phospholipase D Inhibitor 5-Fluoro-2-Indolyl Deschlorohalopemide (FIPI) and D-Alpha Tocopheryl Acid Succinate (α-TOS) for Anti-Metastasis

Liposomes

Particle size

PDI

Zeta potential

Encapsulation efficiency(%)

Drug-loading content (‰)

 

(nm)

 

(mv)

DOX

FIPI

TOS

DOX

FIPI

TOS

Blank-lip

88.58 ± 0.27

0.230 ± 0.004

− 13.80 ± 0.66

-

DOX-lip

84.53 ± 0.45

0.225 ± 0.005

− 27.07 ± 0.38

96.83 ± 1.30

1.33 ± 0.01

-

FIPI-lip

93.58 ± 0.43

0.220 ± 0.017

− 31.63 ± 0.40

96.07 ± 1.85

8.76 ± 0.19

-

TOS-lip

108.60 ± 0.75

0.187 ± 0.007

− 50.33 ± 1.61

94.10 ± 0.03

66.92±0.67

DF-lip

102.73 ± 1.16

0.243 ± 0.009

− 27.97 ± 0.67

96.28 ± 2.50

94.80 ± 1.27

1.32 ± 0.03

8.86 ± 0.06

-

DT-lip

108.40 ± 0.87

0.183 ± 0.016

− 59.40 ± 1.22

94.58 ± 2.87

91.29 ± 2.84

1.19 ± 0.06

65.67±0.59

DFT-lip

119.00 ± 0.80

0.188 ± 0.010

− 58.50 ± 1.04

93.45 ± 3.71

91.46 ± 3.71

91.42 ± 1.94

1.19 ± 0.04

8.69 ± 0.19

65.16±0.18

  1. All data presented here were calculated as the mean ± SD (n = 3) for three different preparations

Navigation